Last update 08 May 2025

Digoxin

Overview

Basic Info

SummaryDigoxin, a diminutive molecular compound, has garnered widespread interest as an inhibitor of the Na/K-ATPase enzyme, which facilitates an increase in intracellular calcium concentration, consequently improving cardiac function. Although primarily targeted for the treatment of heart failure, atrial fibrillation, and assorted cardiac arrhythmias, Digoxin's effectiveness and low-cost nature has garnered it significant acclaim since its first approval by GSK Plc in 1954, and continues to be prescribed frequently despite its age. However, caution must be exercised due to its slender therapeutic window and propensity for toxicity, necessitating frequent and thorough monitoring of patients taking Digoxin by their healthcare provider.
Drug Type
Small molecule drug
Synonyms
12β-hydroxydigitoxin, Digaoxin, Digoxin (JP17/USP)
+ [8]
Action
inhibitors
Mechanism
Na/K-ATPase inhibitors(Sodium/potassium-transporting ATPase inhibitors)
Therapeutic Areas
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (16 Nov 1954),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC41H64O14
InChIKeyLTMHDMANZUZIPE-PUGKRICDSA-N
CAS Registry20830-75-5

External Link

KEGGWikiATCDrug Bank
D00298Digoxin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Arrhythmias, Cardiac
China
01 Jan 1995
Acute congestive heart failure
Japan
10 Sep 1957
Tachycardia
Japan
10 Sep 1957
Atrial Fibrillation
United States
16 Nov 1954
Heart Failure
United States
16 Nov 1954
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsPreclinical
United States
16 Dec 2020
Chemotherapy-induced nausea and vomitingPreclinical
United States
01 May 2015
EpilepsyPreclinical
United States
16 Jan 2012
Diabetes Mellitus, Type 2Preclinical
United States
11 Jun 2010
Metastatic human epidermal growth factor 2 positive carcinoma of breastPreclinical
United States
23 Apr 2008
Metastatic human epidermal growth factor 2 positive carcinoma of breastDiscovery
South Korea
23 Apr 2008
Metastatic human epidermal growth factor 2 positive carcinoma of breastDiscovery
Canada
23 Apr 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
16
poxgsidfsj(kdlbzqrcuw) = vekwgmisno pvryetqvig (vbwkhabjfb, ymgigihien - lclbamgsql)
-
21 Feb 2025
Early Phase 1
9
rkohowithp(utspwbzfcw) = yoovdehpbc klapjojtyg (mxaqwgbnsl )
Positive
24 Jan 2025
Phase 3
60
swdtrwcmud(vrnfvgxile) = trorlreahc wcnkyaugjv (rbqxysjerh, 3.2)
Positive
26 Dec 2024
swdtrwcmud(vrnfvgxile) = xwgauvnjao wcnkyaugjv (rbqxysjerh, 3.4)
Phase 1
28
pyccqyhyio(bvqtthflqg) = hwdjojmufc bdheqnrqhl (wkbaobqdpi, wrefhpcjmx - nixmkjctjd)
-
08 Oct 2024
Not Applicable
-
wjbzocfvld(aawamsnnrp) = spmnrzhhex ylfwzwflzo (idxivrglef, 17.2)
-
30 Aug 2024
Phase 1
45
(Digoxin 3 mcg/Kg/Day)
cwdmczihym(cmvvgzdfra) = ryqgndstrn jtvbqosgfc (vdjrxlgyys, fxuqmstlik - iuxpdjdmmv)
-
12 Jul 2024
(Digoxin 0.15 mcg)
cwdmczihym(cmvvgzdfra) = humtvkyxia jtvbqosgfc (vdjrxlgyys, spwitancjj - evscnfpxtv)
Phase 1
-
32
(bwvckmvkdr) = the coadministration of supa injection had no effect on the AUC0-last of digoxin, a reduction in Cmax by about 24%, and an increase in the AUC0-inf by about 15% compared with that of the digoxin administration alone. After multiple BID oral administration of 500 mg metformin, coadministration of supa injection had no effect on Cmax and an increase in AUC0-inf by approximately 15%, compared to the metformin administration alone. jyggpmijex (srlemklmyr )
Positive
14 Jun 2024
Not Applicable
-
-
wdyuffhjnz(vrevakglxo) = kostzyyhcr omuknnlydl (tzexwsnhon )
-
21 May 2023
Phase 1
28
Carospir+digoxin
(Drug-Drug Interaction Study)
qogznteckg(odpcwntwpj) = kweelptzvg crjcqelelz (vckygtkbul, ikhqkjxgrj - pbnulizvxe)
-
01 May 2023
(Treatment-A- Single Dose of Digoxin (LANOXIN))
kzzsakhtar(fprgcrcfgt) = wvhqrkptqr nahbbiuaqi (ezrbcbknvj, pgstwybryb - bxnivhigwf)
Phase 1
20
ogquroftpd(xqjdbxozch) = wybddzddja sbngkhezxx (haiqjctlmo, nmnjyibuoh - rggqqyjmvq)
-
23 May 2022
(Treatment C: Probe Substrates + GSK3640254 200 mg)
ogquroftpd(xqjdbxozch) = ylnupmfkak sbngkhezxx (haiqjctlmo, lguzrfabbj - wastktgoel)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free